All In MedTech

Device Trial Radar · NCT07124728

Syntrillo Telehealth Stroke Risk Reduction Study

Impact of Syntrillo's Telehealth Service on Stroke Risk Factor Reduction in At-risk Patients

Last checked: Nov 19, 2026Latest source record: Jul 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

11

Actual

Start

Jul 30, 2025

Primary completion

Jul 22, 2026

Study completion Jul 22, 2026

Sponsor

Lead sponsor
Syntrillo, IncAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Aug 15, 2025

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Prevention
FDA-regulated device
No
Who can join
All sexes, from 30 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A prospective, single-arm, open-label study evaluating the impact of Syntrillo's telehealth program on stroke risk factors, particularly blood pressure, among 68 high-risk patients. The 6-month intervention includes personalized remote care with blood pressure monitoring, wearable tracking, and multidisciplinary telehealth visits.

Conditions

  • Hypertension
  • Hypertension (HTN)
  • Stroke Prevention
  • Cardiovascular Risk Factor

Interventions

  • Technology-enabled Telehealth Care PlanBehavioral

    Participants receive a 6 month personalized telehealth intervention via a multidisciplinary care team, delivering care via a secure digital platform, including education, risk assessment, lifestyle coaching, medical history review, and stroke risk reduction planning. The Healthie EHR is used for communication, documentation, and data integration. Syntrillo Navigators and neurology providers conduct onboarding, telemedicine visits, and coordination with patient's primary care providers and care team.

  • Blood Pressure Monitoring DeviceDevice

    Participants will receive a cellular-enabled, FDA-cleared blood pressure monitor supplied by Tenovi. Blood pressure is measured twice daily during baseline and at least once daily throughout the 6-month intervention. Data is transmitted via a secure gateway to the Healthie EHR for real-time monitoring and analysis.

  • Tenovi Smart PillboxDevice

    Participants receive a connected 7-day smart pillbox that detects compartment openings and refills. Medication adherence data is uploaded in real time to a secure dashboard and integrated into the EHR.

  • Wearable Activity Trackers (Fitbit or Apple Watch)Device

    Participants will utilize a commercially available wearable activity tracker to monitor step counts, resting heart rate, and heart rate variability. This data is integrated into the EHR. Devices will be provided if participants do not already own one.

  • Healthie EHROther

    HIPAA-compliant electronic medical record system used for participant management, secure communication, clinical documentation, and device data integration, consisting of custom workflows used for risk tracking and care planning.

  • Secure Messaging Platforms (TigerConnect, Weave, AirCall)Other

    Participants and providers may communicate using secure messaging platforms for appointment reminders, assessments, and care support, to enhance participation engagement and care coordination.

  • Antihypertensive Medication ManagementDrug

    Participants may be prescribed or have existing antihypertensive regimens adjusted (ACE inhibitors, beta blockers, calcium channel blockers, diuretics, etc) by neurologists or nurse practitioners based on individual risk assessments and clinical findings during the study. Changed will be recorded in EHR.

  • Statin Medication ManagementDrug

    Lipid-lowering medications, including statins, may be initiated or adjusted as part of participants' care plans. Medication use is guided by cardiovascular risk and AHA guidelines. Changed will be recorded in EHR.

  • Antiplatelet or Anticoagulant TherapyDrug

    Participants with atrial fibrillation or elevated cardiovascular risk may be started on or have changes to antiplatelet or anticoagulant therapy. Medication decisions are made by neurologist or nurse practitioners during telemedicine visits. Changed will be recorded in EHR.

  • Laboratory Blood Test CollectionProcedure

    Blood samples may be collected at baseline and at 6 months to assess inflammation through high-sensitivity C-reactive protein.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Systolic Blood PressureTime frame: Baseline to 6 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Syntrillo, Inc

    Charlottesville, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.